Dirk Schadendorf
迪尔克·沙登多夫
MD
Professor and Chair, Department of Dermatology; Director, Skin Cancer Center Essen; Director, West German Cancer Center皮肤科主任教授，埃森皮肤癌中心主任
👥Biography 个人简介
Dirk Schadendorf, MD is Professor and Chair of the Department of Dermatology at the University Hospital Essen and Director of the West German Cancer Center, one of Europe's most comprehensive cancer programs. He is a pre-eminent authority on the epidemiology, immunobiology, and treatment of melanoma, with over three decades of contributions to clinical trials and translational research that have shaped European and global practice. Dr. Schadendorf co-authored pivotal analyses of long-term ipilimumab survival data—demonstrating that approximately 20% of patients with advanced melanoma treated with ipilimumab achieve survival beyond three years—an observation that crystallized the concept of an "immune checkpoint inhibitor tail" and profoundly influenced the field's expectations for durable benefit. He has led or co-led major EORTC and European melanoma trials and is among the world's most cited melanoma researchers with an extensive body of work on tumor immune evasion, LDH as a prognostic marker, and resistance to targeted therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Ipilimumab Long-Term Survival: The 20% Plateau
Conducted the landmark pooled survival analysis of 1,861 patients treated with ipilimumab across 12 clinical studies demonstrating a 3-year OS rate of approximately 22%, with a plateau in the survival curve beyond 3 years—providing the first robust evidence for durable long-term benefit from checkpoint inhibitor therapy and the concept of the "immunotherapy tail" in melanoma.
EORTC 18071: Adjuvant Ipilimumab in Stage III Melanoma
Co-led EORTC 18071, the phase III trial demonstrating that adjuvant ipilimumab significantly improved recurrence-free, distant metastasis-free, and overall survival compared with placebo in resected stage III melanoma, establishing the first approved adjuvant immunotherapy for melanoma.
Melanoma Tumor Microenvironment and Immune Evasion
Advanced mechanistic understanding of how melanoma evades immune surveillance through PD-L1 upregulation, IDO expression, regulatory T-cell recruitment, and T-cell exhaustion, and led translational studies characterizing baseline immune infiltration patterns as predictors of immunotherapy response.
European Melanoma Epidemiology and Outcomes Research
Led large-scale European melanoma epidemiology studies and real-world outcomes registries, quantifying incidence trends, documenting the dramatic survival improvements since the introduction of targeted and immune therapies, and identifying disparities in access to modern treatment across European health systems.
Representative Works 代表性著作
Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Journal of Clinical Oncology (2015)
Landmark pooled analysis of 1,861 ipilimumab-treated melanoma patients demonstrating a 3-year OS rate of ~22% and a plateau in the survival curve, establishing the concept of durable long-term benefit from CTLA-4 blockade.
Adjuvant Ipilimumab versus Placebo after Complete Resection of High-Risk Stage III Melanoma (EORTC 18071)
New England Journal of Medicine (2015)
Phase III EORTC 18071 trial demonstrating that adjuvant ipilimumab improved RFS, DMFS, and OS in resected high-risk stage III melanoma, representing the first approved adjuvant immunotherapy for melanoma.
Melanoma
The Lancet (2018)
Comprehensive Lancet Seminar synthesizing melanoma biology, staging, epidemiology, and the modern treatment landscape spanning targeted therapy and immunotherapy, widely used as a field-defining reference.
LDH Serum Level as a Marker for Survival in Patients Treated with Anti-PD-1 and Anti-CTLA-4 in Metastatic Melanoma
European Journal of Cancer (2017)
Large cohort study establishing baseline LDH as a robust independent prognostic biomarker across immunotherapy modalities in metastatic melanoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
关注 迪尔克·沙登多夫 的研究动态
Follow Dirk Schadendorf's research updates
留下邮箱，当我们发布与 Dirk Schadendorf（University Hospital Essen / German Cancer Consortium (DKTK)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment